First-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma

ESMO 2018: Melanoma highlights

IMpower130: PFS and safety of adding atezolizumab to first-line NSCLC therapy

KEYNOTE048: First line pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma

ESMO 2018: Highlights

The TRIBE-2 study for colorectal cancer

Advances in metastatic non small cell lung cancer

Comment on the JAVELIN study: RCC immunotherapy

Use of T-VEC in early metastatic melanoma

KEYNOTE 10: Pembrolizumab vs docetaxel for NSCLC

Expansion from CHECKMATE-032; nivolumab and ipilimumab for metastatic urothelial carcinoma

Avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma